[go: up one dir, main page]

MX2019000882A - Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo. - Google Patents

Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo.

Info

Publication number
MX2019000882A
MX2019000882A MX2019000882A MX2019000882A MX2019000882A MX 2019000882 A MX2019000882 A MX 2019000882A MX 2019000882 A MX2019000882 A MX 2019000882A MX 2019000882 A MX2019000882 A MX 2019000882A MX 2019000882 A MX2019000882 A MX 2019000882A
Authority
MX
Mexico
Prior art keywords
raav
recombinant adeno
associated viral
produced
mode
Prior art date
Application number
MX2019000882A
Other languages
English (en)
Inventor
Fraser Wright John
Qu Guang
Oh Younghoon
Wang Yuhuan
Zhang Haibo
Duncan Laura
Original Assignee
Spark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60992897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019000882(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Spark Therapeutics Inc filed Critical Spark Therapeutics Inc
Publication of MX2019000882A publication Critical patent/MX2019000882A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se proporcionan métodos para producir partículas de vectores de virus adenoasociados recombinantes (rAAV) con una alta recuperación o título alto. También se proporcionan métodos para concentrar vectores de rAAV a una alta concentración, por ejemplo, hasta por 5E+13 (5x101313) genomas de vector por mililitro (Vg/mL) con pocos o ningún agregado de rAAV.
MX2019000882A 2016-07-21 2017-07-21 Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo. MX2019000882A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662365312P 2016-07-21 2016-07-21
PCT/US2017/043291 WO2018017956A2 (en) 2016-07-21 2017-07-21 Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby

Publications (1)

Publication Number Publication Date
MX2019000882A true MX2019000882A (es) 2019-08-12

Family

ID=60992897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000882A MX2019000882A (es) 2016-07-21 2017-07-21 Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo.

Country Status (19)

Country Link
US (1) US20190284576A1 (es)
EP (1) EP3488007B1 (es)
JP (1) JP7153009B2 (es)
KR (3) KR20190045174A (es)
CN (1) CN109790549A (es)
AU (1) AU2017299779B2 (es)
BR (1) BR112019001146A2 (es)
CA (1) CA3031095A1 (es)
DK (1) DK3488007T3 (es)
ES (1) ES2972859T3 (es)
FI (1) FI3488007T3 (es)
IL (2) IL301963A (es)
MX (1) MX2019000882A (es)
MY (1) MY194198A (es)
NZ (1) NZ750016A (es)
PT (1) PT3488007T (es)
RU (1) RU2768045C2 (es)
SG (1) SG11201900366QA (es)
WO (1) WO2018017956A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3831842A1 (en) 2015-09-28 2021-06-09 The University of North Carolina at Chapel Hill Methods and compositions for antibody-evading virus vectors
EP4219724A3 (en) 2016-08-23 2023-09-27 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
SG11202009450SA (en) 2018-04-03 2020-10-29 Stridebio Inc Virus vectors for targeting ophthalmic tissues
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
TW202102525A (zh) 2019-03-21 2021-01-16 美商史崔德生物公司 重組腺相關病毒載體
WO2020210600A1 (en) * 2019-04-11 2020-10-15 Regenxbio Inc. Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
MX2022010050A (es) 2020-02-21 2022-09-05 Akouos Inc Composiciones y metodos para tratar deficiencia auditiva no asociada con la edad en un sujeto humano.
EP3919613B1 (en) * 2020-06-05 2024-08-07 Sartorius BIA Separations d.o.o. Enhanced purification of adeno-associated virus to more effectively remove contaminating dna
BR112023003145A2 (pt) 2020-08-19 2023-05-09 Sarepta Therapeutics Inc Vetores de vírus adenoassociado para tratamento da síndrome de rett
EP4200435A1 (en) * 2020-08-20 2023-06-28 Becton Dickinson and Company Blood cell lysing agent for isolating bacteria from blood culture
EP4431600A1 (en) * 2021-11-12 2024-09-18 Agc Inc. Virus purification method
JP2023141423A (ja) * 2022-03-24 2023-10-05 国立大学法人 東京大学 ウイルスの精製方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1506287B1 (en) 2002-05-14 2007-04-25 Merck & Co., Inc. Methods of adenovirus purification
MX360727B (es) 2004-06-01 2018-11-14 Genzyme Corp Composiciones y metodos para evitar la agregacion del vector aav.
EP1841474A2 (en) * 2005-01-25 2007-10-10 Wyeth Research Ireland Limited Method for diafiltration
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CN102257134B (zh) * 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
CN102216450B (zh) * 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
FR2944292B1 (fr) * 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
IN2012DN06629A (es) * 2010-01-28 2015-10-23 Philadelphia Children Hospital
CN103189507A (zh) * 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
TR201903248T4 (tr) * 2013-03-15 2019-03-21 Glaxosmithkline Biologicals Sa Rna saflaştırma yöntemleri.
CA2922996C (en) * 2013-10-07 2023-03-21 Novartis Ag Treated filter
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
CA3008142A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Gene therapy for treating familial hypercholesterolemia

Also Published As

Publication number Publication date
BR112019001146A2 (pt) 2019-04-30
CN109790549A (zh) 2019-05-21
KR20220162834A (ko) 2022-12-08
AU2017299779A1 (en) 2019-01-31
IL264270A (en) 2019-02-28
EP3488007B1 (en) 2023-12-20
NZ750016A (en) 2025-09-26
WO2018017956A2 (en) 2018-01-25
JP2019524101A (ja) 2019-09-05
JP7153009B2 (ja) 2022-10-13
RU2019104759A (ru) 2020-08-21
AU2017299779B2 (en) 2021-12-02
EP3488007A2 (en) 2019-05-29
RU2019104759A3 (es) 2020-11-17
US20190284576A1 (en) 2019-09-19
EP3488007A4 (en) 2020-01-01
KR102695908B1 (ko) 2024-08-14
KR20190045174A (ko) 2019-05-02
PT3488007T (pt) 2024-03-14
MY194198A (en) 2022-11-21
FI3488007T3 (fi) 2024-03-19
IL301963A (en) 2023-06-01
SG11201900366QA (en) 2019-02-27
DK3488007T3 (da) 2024-02-19
WO2018017956A3 (en) 2018-03-08
CA3031095A1 (en) 2018-01-25
RU2768045C2 (ru) 2022-03-23
KR20240126073A (ko) 2024-08-20
ES2972859T3 (es) 2024-06-17

Similar Documents

Publication Publication Date Title
MX2019000882A (es) Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo.
MX2019001938A (es) Metodos para detectar aav.
MX2019004499A (es) Sistemas de replicón de virus recombinante y usos de estos.
BR112018071180A2 (pt) métodos de reforço potência biológica de baculovirus system-produzido vírus adeno-associado recombinante
Henry et al. Tools from viruses: bacteriophage successes and beyond
ECSP17074016A (es) Producción de vectores adeno-asociados de gran tamaño
MX2016010649A (es) Vector de virus adeno-asociado.
EA201892648A1 (ru) Вирусы пичинде с трехсегментным геномом в качестве векторных вакцин
MX2017012097A (es) Variantes de virus adenoasociado y métodos de uso de estas.
ZA202004980B (en) A modified raav capsid protein for gene therapy
MX2020005282A (es) Vector para la produccion de particulas aav.
RU2019107976A (ru) Композиция вакцины
MX2019000962A (es) Novedosas proteinas de la capside del virus adenoasociado.
MX2019000252A (es) Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos.
DK2277996T3 (da) Fremgangsmåder til fremstilling af præparationer af rekombinante aav-virioner, der i hovedsagen er fri for tomme capsider
AU2017261249A1 (en) Adeno-associated virus polynucleotides, polypeptides and virions
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
BR112022016025A2 (pt) Neoantígenos expressos em mieloma múltiplo e seus usos
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
MY188494A (en) High-growth enterovirus 71 strains and vaccines
EA202191919A1 (ru) Неоантигены предстательной железы и их применение
EA201990955A1 (ru) Разработка капсидов aav
AR104216A1 (es) Producción de vectores adeno-asociados de gran tamaño
MY185444A (en) Enterovirus 71 antiviral peptides
EA202191862A2 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения